Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 7/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666301 | 1.00 | CASP2 (0.59) | CASP2FAAHEPHX2ACE2NAAA | |
| SCHEMBL10088131 | 0.98 | CASP2 (0.56) | CASP2FAAHEPHX2ACE2NAAA | |
| SCHEMBL10083874 | 0.92 | EPHX2 (0.71) | FAAHEPHX2SLC6A5KDM4EMEN1 | |
| SCHEMBL13706976 | 0.89 | EPHX2 (0.54) | CASP2FAAHEPHX2KDM4EMAPK1 | |
| SCHEMBL13706974 | 0.89 | EPHX2 (0.54) | CASP2FAAHEPHX2KDM4EMAPK1 | |
| SCHEMBL16944361 | 0.89 | EPHX2 (0.54) | CASP2FAAHEPHX2KDM4EMAPK1 | |
| SCHEMBL12891255 | 0.89 | EPHX2 (0.54) | CASP2FAAHEPHX2KDM4EMAPK1 | |
| SCHEMBL12666256 | 0.89 | EPHX2 (0.54) | CASP2FAAHEPHX2KDM4EMAPK1 | |
| SCHEMBL12891252 | 0.89 | EPHX2 (0.54) | CASP2FAAHEPHX2KDM4EMAPK1 | |
| SCHEMBL19069567 | 0.89 | CASP2 (0.59) | CASP2FAAHEPHX2ACE2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CASP2 2622/4885FAAH 1647/4885EPHX2 1083/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | CASP2 2622/4885FAAH 1647/4885EPHX2 1083/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CASP2 2622/4885FAAH 1628/4885EPHX2 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.